American health regulators revealed that they will not be approving any generic forms of OxyContin unless they come with abuse-curbing properties of a reformulated version of the painkiller drug.
American health regulators revealed that they will not be approving any generic forms of OxyContin unless they come with abuse-curbing properties of a reformulated version of the painkiller drug. Manufacturer Perdue Pharma discontinued original OxyContin (oxycodone hydrochloride) in 2010 after the US Food and Drug Administration approved a new version of the drug that is more difficult to snort or inject.
"Because original OxyContin provides the same therapeutic benefits as reformulated OxyContin, but poses an increased potential for certain types of abuse, the FDA has determined that the benefits of original OxyContin no longer outweigh its risks," the FDA said in a statement late Tuesday.
"Accordingly, the agency will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of original OxyContin."
FDA Deputy Director Douglas Throckmorton said that "while both original and reformulated OxyContin are subject to abuse and misuse," reformulated OxyContin is more difficult to crush or melt down, making it harder to snort or inject.
"When FDA finds that a new formulation has abuse deterrent properties, the agency has the authority to require generics to have abuse-deterrent properties also," regulators said, indicating the ruling could apply to other medicines.
OxyContin sales generated $2.8 billion in 2012, according to IMS Health, an industry information service. The latest FDA ruling extends Perdue Pharma's patent protection over the drug.
Advertisement
OxyContin shot to popularity in the last decade, largely in rural parts of the United States, gaining the nickname "Hillbilly Heroin."
Advertisement
Source-AFP